Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) is hosting an investor and analyst meeting focusing on its POLB 001 Oncology Programme, targeting cytokine release syndrome (CRS) associated with cancer immunotherapies.
CRS is a life-threatening condition that has been a significant barrier to the broader adoption of cancer immunotherapies.
The event, being held on 6 November from 2.30pm, will be led by CEO Jeremy Skillington, and will feature presentations from key opinion leaders in the field, as well as a patient advocate.
A question-and-answer session with Poolbeg's senior management and guest speakers will follow the presentations.
To sign up, click here.